nach oben

Current Obesity Reports

Erschienen in:

06.07.2020 | Metabolism (M Dalamaga, Section Editor)

Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity?

verfasst von: Christina Tsigalou, Natalia Vallianou, Maria Dalamaga

Erschienen in: Current Obesity Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

During the last decades, obesity and autoimmune disorders have shown a parallel significant rise in industrialized countries. This review aims at providing a comprehensive update of the relationship between the adipose tissue in obesity and autoimmune disorders, highlighting the underlying mechanisms with a particular emphasis on adipokines and pro-inflammatory cytokines, the impaired B cell activity, and the production of natural and pathogenic autoantibody repertoire in the context of obesity.

Recent Findings

Obesity is related to a higher risk of rheumatoid arthritis, psoriasis and psoriatic arthritis, multiple sclerosis, and Hashimoto’s thyroiditis, while it may promote inflammatory bowel disorders and type 1 diabetes mellitus. Interestingly, subjects with obesity present more severe forms of these autoimmune disorders as well as decreased therapeutic response. Both obesity and autoimmune disorders present elevated levels of leptin, resistin, and visfatin. Autoantibody production, a hallmark of autoimmune disorders, has been demonstrated in obese animal models and human subjects. Obesity results in deficiencies of the human self-tolerance mechanisms by promoting pro-inflammatory processes, reducing Bregs as well as Tregs, and the latter resulting in increased Th17 and Th1 cells, creating the perfect milieu for the development of autoimmune disorders.

Summary

More mechanistic, animal, and clinical studies are required to delineate the exact mechanisms underlying auto-reactivity in obesity as well as the adipose-immune crosstalk for potential successful therapeutic strategies.

Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–50.

Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.PubMed

Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–23.

Organization WH, UN-Habitat. Global report on urban health: equitable healthier cities for sustainable development. World Health Organization; 2016.: 236.

Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: current evidence and perspectives. Curr Obes Rep. 2019;8(3):317–32.PubMed

•• Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981–1000. Versini et al. present a significant review regarding obesity and autoimmune disorders, with emphasis on major autoimmune diseases and proposed mechanisms of obesity-associated autoimmunity.PubMed

Shoenfeld Y. Everything is autoimmune until proven otherwise. Clin Rev Allergy Immunol. 2013;45(2):149–51.PubMed

Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obes Silver Spring Md. 2015;23(3):512–8.

Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.PubMed

10.

Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113(9):1009–23.PubMedPubMedCentral

11.

Lu J, Zhao J, Meng H, Zhang X. Adipose tissue-resident immune cells in obesity and type 2 diabetes. Front Immunol. 2019;10:1173.PubMedPubMedCentral

12.

Macdougall CE, Wood EG, Loschko J, Scagliotti V, Cassidy FC, Robinson ME, et al. Visceral adipose tissue immune homeostasis is regulated by the crosstalk between adipocytes and dendritic cell subsets. Cell Metab. 2018;27(3):588–601.e4.PubMedPubMedCentral

13.

Kratz M, Coats BR, Hisbert KB, Hagman D, Mutskov V, Peris E, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 2014;20(4):614–25.PubMedPubMedCentral

14.

West-Eberhard MJ. Nutrition, the visceral immune system, and the evolutionary origins of pathogenic obesity. Proc Natl Acad Sci. 2019;116(3):723–31.PubMed

15.

Lumey LH, Stein AD, Susser E. Prenatal famine and adult health. Annu Rev Public Health. 2011;32:237–62.PubMed

16.

Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8(12):923–34.PubMedPubMedCentral

17.

Add Rakhshandehroo M, Kalkhoven E, Boes M. Invariant natural killer T cells in adipose tissue: novel regulators of immune-mediated metabolic disease. Cell Mol Life Sci. 2013;70(24):4711–27.

18.

Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):217–26.PubMedPubMedCentral

19.

Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–85.PubMed

20.

Blüher M. The distinction of metabolically “healthy” from “unhealthy” obese individuals. Curr Opin Lipidol. 2010;21(1):38–43.PubMed

21.

Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156(1–2):20–44.PubMedPubMedCentral

22.

Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43(4):157–68.PubMed

23.

Karampela I, Christodoulatos GS, Dalamaga M. The role of adipose tissue and adipokines in sepsis: inflammatory and metabolic considerations, and the obesity paradox. Curr Obes Rep. 2019;8(4):434–57.PubMed

24.

• Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA. Mantzoros CSLeptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 2013;18(1):29–42.PubMed

25.

Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34(3):377–412.

26.

Stofkova A. Resistin and visfatin: regulators of insulin sensitivity inflammation and immunity. Endocr Regul. 2010;44(1):25–36.PubMed

27.

•• Dalamaga M. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med. 2014;8(1):107–18. Dalamaga have focused on inflammation as the major pathogenetic mechanism associating resistin with cancer and obesity.

28.

Krysiak R, Handzlik-Orlik G, Okopien B. The role of adipokines in connective tissue diseases. Eur J Nutr. 2012;51(5):513–28.PubMedPubMedCentral

29.

Dalamaga M, Christodoulatos GS, Mantzoros CS. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: diagnostic and therapeutic perspectives and challenges. Metabolism. 2018;82:72–87.PubMed

30.

Sun Y, Xun K, Yang C, Zhao H, Bi H, Chen X, et al. Adiponectin: an unlocking adipokine. Cardiovasc Ther. 2009;27(1):59–75.PubMed

31.

Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–94.PubMedPubMedCentral

32.

Dalamaga M, Christodoulatos GS. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Horm Mol Biol Clin Invest. 2015;23(1):5–20.

33.

Kosaraju R, Guesdon W, Crouch MJ, Teague HL, Sullivan EM, Karlsson EA, et al. B cell activity is impaired in human and mouse obesity and is responsive to an essential fatty acid upon murine influenza infection. J Immunol Baltim Md. 2017;198(12):4738–52.

34.

Shaikh SR, Haas KM, Beck MA, Teague H. The effects of diet-induced obesity on B cell function. Clin Exp Immunol. 2015;179(1):90–9.PubMed

35.

•• Tedder TF. B10 cells: a functionally defined regulatory B cell subset. J Immunol. 2015;194(4):1395. This review focused on the development, phenotype, and role of B10 cells in autoimmunity and inflammation in mouse models.PubMed

36.

Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006;176(2):705–10.PubMed

37.

Harmon DB, Srikakulapu P, Kaplan JL, Oldham SN, McSkimming C, Garmey JC, et al. Protective role for B-1b B cells and IgM in obesity-associated inflammation, glucose intolerance, and insulin resistance. Arterioscler Thromb Vasc Biol. 2016;36(4):682–91.

38.

Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 2011;17(5):610–7.

39.

Ballak DB, Stienstra R, Hijmans A, Joosten LAB, Netea MG, Tack CJ. Combined B- and T-cell deficiency does not protect against obesity-induced glucose intolerance and inflammation. Cytokine. 2013;62(1):96–103.PubMed

40.

DeFuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A. 2013;110(13):5133–8.

41.

• Frasca D, Diaz A, Romero M, Vazquez T, Blomberg BB. Obesity induces pro-inflammatory B cells and impairs B cell function in old mice. Mech Ageing Dev. 2017;162:91–9. Frasca et al. have embarked on characterizing B cells and their functionality in obesity and obesity-associated inflammation in mouse model.PubMedPubMedCentral

42.

Wu L, Parekh VV, Hsiao J, Kitamura D, Van Kaer L. Spleen supports a pool of innate-like B cells in white adipose tissue that protects against obesity-associated insulin resistance. Proc Natl Acad Sci U S A. 2014;111(43):E4638–47.PubMedPubMedCentral

43.

Barengolts E. Gut microbiota, prebiotics, probiotics, and synbiotics in management of obesity and prediabetes: review of randomized controlled trials. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2016;22(10):1224–34.

44.

Winer DA, Winer S, Chng MHY, Shen L, Engleman EG. B lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell Mol Life Sci CMLS. 2014;71(6):1033–43.PubMed

45.

Nishimoto S, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Murata C, et al. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv. 2016;2(3):e1501332.

46.

Nikiphorou E, Fragoulis GE. Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis. 2018;10(8):157–67.PubMedPubMedCentral

47.

Munger KL, Bentzen J, Laursen B, Stenager E, Koch-Henriksen N, Sørensen TIA, et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler Houndmills Basingstoke Engl. 2013;19(10):1323–9.

48.

Pakpoor J, Pakpoor J. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013;81(15):1366.PubMed

49.

Hedström AK, Lima Bomfim I, Barcellos L, Gianfrancesco M, Schaefer C, Kockum I, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology. 2014;82(10):865–72.PubMedPubMedCentral

50.

Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler. 2011;17(1):2–15.

51.

Emamgholipour S, Eshaghi SM, Hossein-nezhad A, Mirzaei K, Maghbooli Z, Sahraian MA. Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS One. 2013;8(10):e76555.PubMedPubMedCentral

52.

Lu B, Hiraki L, Sparks JA, Malspeis S, Chen C-Y, Awosogba JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis. 2014;73(11):1914–22.PubMedPubMedCentral

53.

Crowson CS, Matteson EL, Davis JM III, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res. 2013;65(1):71–7.

54.

Ajeganova S, Andersson ML, Hafström I. Group for the BS. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term follow-up from disease onset. Arthritis Care Res. 2013;65(1):78–87.

55.

Katz P, Yazdany J, Julian L, Trupin L, Margaretten M, Yelin E, et al. Impact of obesity on functioning among women with systemic lupus erythematosus. Arthritis Care Res. 2011;63(10):1357–64.

56.

Chaiamnuay S, Bertoli AM, Fernández M, Apte M, Vilá LM, Reveille JD, et al. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort. JCR J Clin Rheumatol [Internet]. 2007;13(3). Available from: https://journals.lww.com/jclinrheum/Fulltext/2007/06000/The_Impact_of_Increased_Body_Mass_Index_on.5.aspx.

57.

Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54.PubMedPubMedCentral

58.

Carrascosa JM, Rocamora V, Fernandez-Torres RM, Jimenez-Puya R, Moreno JC, Coll-Puigserver N, et al. Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relación entre psoriasis y obesidad e implicaciones terapéuticas. Actas Dermo-Sifiliográficas. 2014;105(1):31–44.

59.

Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity? Expert Opin Pharmacother. 2019;20(11):1303–8.PubMed

60.

Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010;146(7):721–6.PubMed

61.

Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A, Veneziano L., Pellacani G., the Psoriasis Emilia Romagna Study Group Psoriasis Emilia Romagna Study Group. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 2014;170(3):634–642.

62.

Harpsøe MC, Basit S, Andersson M, Nielsen NM, Frisch M, Wohlfahrt J, et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int J Epidemiol. 2014;43(3):843–55.

63.

Stratigou T, Dalamaga M, Antonakos G, Marinou I, Vogiatzakis E, Christodoulatos GS, et al. Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors. Endocrine. 2018;61(1):83–9.

64.

Song RH, Wang B, Yao QM, Li Q, Jia X, Zhang JA. The impact of obesity on thyroid autoimmunity and dysfunction: a systematic review and meta-analysis. Front Immunol. 2019;10:2349.PubMedPubMedCentral

65.

Marzullo P, Minocci A, Tagliaferri MA, Guzzaloni G, Di Blasio A, De Medici et al. Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. J Clin Endocrinol Metab 2010;95(8):3965–3972.

66.

Wang S, Baidoo SE, Liu Y, Zhu C, Tian J, Ma J, et al. T cell-derived leptin contributes to increased frequency of T helper type 17 cells in female patients with Hashimoto’s thyroiditis. Clin Exp Immunol. 2013;171(1):63–8.

67.

Fischer-Posovszky P, Funcke JB, Wabitsch M. Biologically inactive leptin and early-onset extreme obesity. N Engl J Med. 2015;372(13):1266–7.PubMed

68.

Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleinewietfeld M. Role of “Western Diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2013;14(1):404.

69.

Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol. 2001;1(6):983–93.PubMed

70.

•• Boyden S. Autoimmunity and inflammation. Nature. 1964;201(4915):200–1. Boyden has first described the link of autoimmunity to inflammatory processes.PubMed

71.

George J, Gilburd B, Shoenfeld Y. The emerging concept of pathogenic natural autoantibodies. Hum Antibodies. 1997;8(2):70–5.PubMed

72.

Avrameas S, Ternynck T. Natural autoantibodies: the other side of the immune system. Res Immunol. 1995;146(4):235–48.PubMed

73.

• Neiman M, Hellström C, Just D, Mattsson C, Fagerberg L, Schuppe-Koistinen I, et al. Individual and stable autoantibody repertoires in healthy individuals. Autoimmunity. 2019;52(1):1–11. Neiman et al. have studied the autoantibody production in healthy individuals, highlighting that autoantibody repertoire is stable over time and highly individualized.PubMed

74.

Arai S, Maehara N, Iwamura Y, Honda S, Nakashima K, Kai T, et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep. 2013;3(4):1187–98.

75.

Petta I, Fraussen J, Somers V, Kleinewietfeld M. Interrelation of diet, gut microbiome, and autoantibody production. Front Immunol. 2018;6(9):439.

76.

Bennett JL, O’Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflammation. 2015;7:2(3):e104.

77.

Meffre E, O’Connor KC. Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev. 2019;292(1):90–101.PubMed

78.

Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;11:168(15):1609–16.

79.

Frasca D, Ferracci F, Diaz A, Romero M, Lechner S, Blomberg BB. Obesity decreases B cell responses in young and elderly individuals. Obes Silver Spring Md. 2016;24(3):615–25.

80.

• Frasca D, Diaz A, Romero M, Thaller S, Blomberg BB. Secretion of autoimmune antibodies in the human subcutaneous adipose tissue. PLoS One. 2018;13(5):e0197472. Frasca et al. have studied extensively the production of autoantibodies in the human SAT, instead of VAT, finding significant production of autoantibodies in the SAT also.PubMedPubMedCentral

81.

•• Frasca D, Diaz A, Romero M, Blomberg B. Mechanisms for secretion of antibodies with “anti-self” reactivity by the human obese adipose tissue. J Immunol. 2019;202(1 Suppl):179.4. Frasca et al. have documented and reported mechanisms of production of autoantibodies in obesity among humans.

82.

• Hanna Kazazian N, Wang Y, Roussel-Queval A, Marcadet L, Chasson L, Laprie C, et al. Lupus autoimmunity and metabolic parameters are exacerbated upon high fat diet-induced obesity due to TLR7 signaling. Front Immunol. 2019;4(10):2015. Kazazian et al. have worked on high-fat diet-induced obesity and the pathway of TLR7 regarding the pathogenesis of obesity.

Titel: Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity?
verfasst von: Christina Tsigalou
Natalia Vallianou
Maria Dalamaga
Publikationsdatum: 06.07.2020
Verlag: Springer US
Erschienen in: Current Obesity Reports / Ausgabe 3/2020
Elektronische ISSN: 2162-4968
DOI: https://doi.org/10.1007/s13679-020-00397-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Review of the Experience of Weight-Based Stigmatization in Romantic Relationships

From the Knife to the Endoscope—a History of Bariatric Surgery

Predicting Responses to Bariatric and Metabolic Surgery

Treatment Options for Poor Responders to Bariatric Surgery

Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations